Pharmadrug (PHRX) AI Stock Analysis

• Market Cap: C$1.07M
• Dividend Yield: N/A
• Average Volume (3M): 116.68K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.63
• Revenue Growth: N/A
• EPS Growth: -2291.11%
• Country: CA
• Employees: 9
• Sector: Healthcare
• Sector Strength: 39
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 106,734,380
• 10 Day Avg. Volume: 295,808
• 30 Day Avg. Volume: 116,677
• PEG Ratio: >-0.01
• Price to Book (P/B): -1.06
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.42
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Pharmadrug's overall score is significantly impacted by its weak financial performance, characterized by zero revenue, high leverage, and negative cash flows. While there is some short-term technical momentum, the lack of profitability and negative valuation metrics pose substantial risks to potential investors.

Pharmadrug Business Overview & Revenue Model

Company Description

Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally-derived approved drugs. It also imports and distributes medical cannabis to pharmacies in Germany and rest of the European Union; and owns and operates Super Smart, an entity building to elevate the use of functional mushrooms and psilocybin mushrooms. In addition, the company engages in the researching and reformulating established natural medicines. It has a research agreement with the University of Michigan to evaluate N, N-dimethyltryptamine's (DMT) potential role in normal, diseased, and altered states of consciousness, as well as an agreement with Southwest Research Institute for initiating non-clinical and clinical manufacturing of cepharanthine; and clinical trial agreement with Johns Hopkins University to conduct a clinical study comparing acute and enduring psychological and neural effects of DMT and an undisclosed potently active comparator molecule. The company was formerly known as Aura Health Inc. and changed its name to Pharmadrug Inc. in October 2019. The company is based in Toronto, Canada.

How the Company Makes Money

Pharmadrug makes money primarily through the sale and licensing of its pharmaceutical products. The company's revenue streams include direct sales of its therapies to healthcare providers, partnerships with other pharmaceutical firms for the co-development and distribution of drugs, and licensing agreements that allow third parties to market and sell its products in different regions. Pharmadrug may also engage in research collaborations with academic institutions and other biotech companies, generating additional income through milestone payments and royalties. Furthermore, the company could potentially benefit from government grants or incentives for developing innovative treatments in under-served therapeutic areas.

Pharmadrug Financial Statement Overview

Summary

Pharmadrug is in a precarious financial position with no revenue and significant losses across all financial statements. The negative equity and high leverage are serious concerns, and the negative cash flows further underline the company's struggles. Urgent strategic intervention is required to stabilize and improve the financial health of the company.

Income Statement

The company has reported zero revenue in the latest period, with significant negative margins across the board. Both the gross profit and net income are heavily negative, indicating substantial losses. The lack of revenue growth and declining profitability metrics signal challenging times for the company.

Balance Sheet

The company has a negative stockholders' equity, which is a significant concern, reflecting high leverage and financial instability. The debt levels are substantial compared to assets, posing potential risks for financial sustainability. The equity ratio indicates that liabilities exceed assets, further highlighting financial distress.

Cash Flow

The operating cash flow is negative, indicating the company is not generating enough cash from its core operations. The free cash flow is also negative, suggesting cash flow challenges. While there are inflows from investing activities, the overall cash flow position is weak, hinting at potential liquidity issues.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	494.99K	683.67K	610.58K
	Gross Profit
-51.34K	-26.22K	-2.26K	100.86K	182.04K	253.25K
	EBIT
-2.19M	-1.34M	-2.43M	-5.11M	-3.82M	-5.09M
	EBITDA
-13.72M	-1.34M	-2.34M	-4.21M	-4.28M	-5.73M
	Net Income Common Stockholders
-13.11M	-13.20M	-3.06M	-5.87M	-5.51M	-6.54M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
155.12K	423.06K	329.24K	1.30M	4.40M	73.68K
	Total Assets
1.06M	1.20M	12.11M	19.52M	13.69M	10.38M
	Total Debt
960.20K	1.77M	1.42M	866.37K	1.13M	3.12M
	Net Debt
805.08K	1.36M	1.41M	-91.62K	-1.01M	3.05M
	Total Liabilities
1.55M	2.66M	3.28M	2.66M	3.12M	5.92M
	Stockholders Equity
-490.32K	-1.70M	8.84M	16.87M	9.33M	2.98M
Cash Flow		Free Cash Flow
-1.13M	-671.88K	-2.26M	-4.17M	-1.43M	-2.36M
	Operating Cash Flow
-1.13M	-671.88K	-2.26M	-4.13M	-1.41M	-2.34M
	Investing Cash Flow
741.24K	995.04K	77.58K	1.48M	3.78M	-7.32M
	Financing Cash Flow
353.39K	225.51K	843.25K	776.97K	132.24K	9.51M

Pharmadrug Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRX, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.31 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PHRX.

Pharmadrug Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STPH	57 Neutral	C$970.72K	2.87	-11.62%	―	―	-57.35%
Sector *	52 Neutral	$5.14B	3.39	-43.55%	2.83%	16.49%	-0.19%
PHRX	29 Underperform	C$1.07M	―	-405.57%	―	―	-2291.11%
MGW	21 Underperform	C$969.81K	―		―	―	81.21%
ORI	21 Underperform	C$797.31K	―	6.34%	―	―	-314.29%

Pharmadrug Corporate Events

PharmaDrug Completes Strategic Debenture Issuance

PharmaDrug Inc. has successfully issued over $412,000 in debentures to replace its outstanding secured convertible debentures, along with over 8 million common share purchase warrants. These debentures, convertible into common shares at $0.05 each, are secured by a general security agreement and carry no interest unless unpaid at maturity, marking a strategic financial move for the company.